# US 2014/0154705 A1 · Antibodies to oxidized ldl > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0154705 A1 - Document ID: US20140154705A1 - Status: Published application - Kind: A1 - Application number: 13/587,914 - Filed: 2012-08-16 - Published: 2014-06-05 - Earliest claimed: 2012-08-16 - Inventors: Victor Manneh - Web page: https://patentgrep.com/patent/US20140154705A1 ## CPC - G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)} - C07K 16/18: against material from animals or humans - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract A method is described for obtaining antibodies binding specifically to an epitope resulting from in vivo modification of a biomolecule or biomolecular complex, where the in vivo modification results from expression of a transgene in an animal. An example of such a biomolecule or biomolecular complex is LDL and an example of such a transgene is human myeloperoxidase. Resulting antibodies and methods of using the antibodies are also described. ## Claims ### Claim 1 A method for producing antibodies specific for in vivo-modified biomolecules, comprising screening monoclonal antibody clones for specific binding activity to an in vivo modification epitope on a biomolecule or biomolecular complex, wherein said antibody clones are derived from a transgenic animal expressing a transgene, wherein expression of said transgene results in said in vivo modification or an increase in the level of said in vivo modification; and identifying antibody clones having said specific binding activity. ### Claim 2 (depends on 1) The method of claim 1, wherein said biomolecule or biomolecular complex is low density lipoprotein (LDL). ### Claim 3 (depends on 1) The method of claim 1, where said transgene is human myeloperoxidase and said modified biomolecule is a component of oxidized low density lipoprotein (oxLDL). ### Claim 4 (depends on 1) The method of claim 1, wherein said transgenic animal is a transgenic mouse. ### Claim 5 (depends on 1) The method of claim 1, wherein said transgene is a human gene. ### Claim 6 (depends on 1) The method of claim 1, wherein antibodies binding specifically to said in vivo modification are selected from a plurality of hybridoma cell lines derived from said transgenic animal. ### Claim 7 (depends on 1) The method of claim 1, wherein antibodies binding specifically to said in vivo modification are selected by panning a plurality of clones in a phage display library. ### Claim 8 (depends on 1) The method of claim 1, wherein said selected antibody is an intact antibody. ### Claim 9 (depends on 1) The method of claim 1, wherein said antibody fragment is an Fab fragment, an Fab′ fragment, a scFv fragment, or a sdFv fragment. ### Claim 10 (depends on 2) The method of claim 2, wherein said antibody preferentially binds to a plurality of different forms of oxidized LDL, including at least one of mpo-LDL, MDA-LDL, and cu-LDL as compared to binding to unmodified LDL. ### Claim 11 An isolated monoclonal antibody, comprising a monoclonal antibody or antibody fragment derived from a transgenic animal expressing a transgene, wherein expression of said transgene results in in vivo modification of biomolecules and said antibody or antibody fragment binds specifically to an epitope containing at least a part of said in vivo modification. ### Claim 12 (depends on 11) The monoclonal antibody of claim 11, wherein said antibody comprises a variable sequence preferentially binding to a modification epitope resulting from expression of human myeloperoxidase in a non-human animal. ### Claim 13 A kit for determining the presence or amount of oxidized LDL (oxLDL) in a sample, comprising at least one antibody that specifically binds to an oxidized epitope in oxLDL, wherein said antibody is derived from a transgenic animal expressing human myeloperoxidase and preferentially binds to mpo-LDL rather than un-modified LDL. ### Claim 14 (depends on 13) The kit of claim 13, comprising a plurality of single-use aliquots of said antibody. ### Claim 15 (depends on 13) The kit of claim 13, comprising a plurality of lateral flow assay devices, wherein a single use aliquot of said antibody is present in each said assay devices. ### Claim 16 A method for determining the presence or amount of oxidized LDL (oxLDL) in a sample, comprising contacting said sample with at least one antibody which specifically binds to oxLDL, wherein said at least one antibody is derived from a transgenic animal expressing a transgene which results in in vivo oxidation of LDL; and detecting binding of said at least one antibody to LDL as an indication of the presence or amount of oxLDL in said sample. ### Claim 17 (depends on 16) The method of claim 16, wherein said transgene is human myeloperoxidase.